Xagenic

/news/xagenic-announces-second-closing-255m-series-b-financing
Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Series A,B,C
Fund:
Compass Rose
Validation of the GenEplex platform for clinically accepted leukemia biomarkers

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.